Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials
click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.


Alan Franciscus

Editor-in-Chief

HCV Advocate



Tuesday, September 15, 2015

Women Living with HIV Face Higher Rates of Cancer Diagnosis: Study


Vancouver, BC [September 15, 2015] Due to the introduction of modern highly active antiretroviral therapy (HAART), people living with HIV are now much less likely to develop AIDS-related cancers, which were characteristic of the epidemic in the 1980s. However, a new study published in HIV Medicine shows women living with HIV still have a higher likelihood of being diagnosed with certain cancers, when compared with the general population.

While rates of AIDS-defining malignancies may be decreasing over time, there has been an observed increase in non-AIDS defining malignancies among women living with HIV compared to the general population. This trend primarily involves cancers with underlying infectious causes such as human papillomavirus (HPV) and hepatitis.

“This research suggests chronic inflammation, immune-suppression, aging and viral infections may be contributing to the cancer risk,” said Dr. Robert Hogg, Senior Research Scientist at the BC Centre for Excellence in HIV/AIDS (BC-CfE) and Professor at Simon Fraser University. Dr. Hogg is the thesis supervisor for Kate Salters, the study’s main author. “The study highlights the importance of ongoing access to HIV care and cancer screening practices that are specific to the risks facing women living with HIV. With sustained treatment, women with HIV are now able to live longer, healthier lives – making it increasingly important to address emerging health needs.”

Read more....

Monday, September 14, 2015



Big Questions about Hepatitis C 
Answers to some common questions about hepatitis C and its treatment. 

—Lucinda K. Porter, RN

Do you lay awake pondering questions about hepatitis C? If so, you probably need some answers so you can sleep better. This month, I answer some common questions I hear from patients. 

I just finished hepatitis C treatment. My final hepatitis C viral (HCV) load test result was “not detected.” I was hoping that my viral load would be “negative” rather than “not detected.” My doctor was happy with the result. What does this mean?

Undetected (or nondetected) means that hepatitis C is gone, and presumably all gone. The confusion over this test is because viral load tests don’t measure down to zero. Viral load tests vary. For instance, the Abbott RealTime HCV assay (assay is a fancy word for a test that determines and counts the ingredients of something) measures down to 12 IU/mL in a 0.5 mL sample of blood. This means that if you have 12 IU/ml of hepatitis C (HCV RNA) in your blood, the test can measure it. If you have less than 12, the test can’t measure it. In some cases, the test may not even see the virus.

Each test has its own detection range, some 
lower than others. The main thing is this: 

“Not detected” = negative for hepatitis C

“Detected” or an actual number of how much 
HCV RNA you have = positive for hepatitis C

If you are concerned that you may have some residual HCV swimming around in your body, that will someday become a full-blown infection, rest assured, as this is quite unlikely. Hep C replicates a trillion times a day, so “not detected” might as well be zero. It is extremely unlikely that a small amount of HCV will remain alive in your body without having replicated to much higher amounts. In fact, viral load tends to replicate at much higher numbers when treatment fails.
My HCV load was nondetectable and my doctor says I am cured. How do I know for sure that the virus won’t come back?

Doctors have been treating hepatitis C for more than two decades. In the beginning, only a small percentage of patients responded to treatment. We weren’t sure these patients were permanently cured, so the term sustained viral response (SVR) was used. Over time, we learned that a sustained viral response (SVR) equals a cure, and that once gone, hepatitis C does not return unless there is exposure to a new infection. The rare exception to this is when a patient has cryoglobulinemia or a rare immune condition.  I’ve worked in this field for 18 years, have crossed paths with thousands of patients, and have never known anyone who had an SVR but the virus came back, except for those who were reinfected or had an error in their testing procedure.

So, are you saying that if I am cured, I can get hep C again?

Yes. The chance of a hepatitis C reinfection with hepatitis C is low, but it is not impossible. Risk of reinfection is higher if you are HIV positive or use injection drugs. 

In a poster presented this year at CROI in Seattle, Andrew Hill and colleagues analyzed data from 11,071 patients in 66 studies. (Five-Year Risk of Late Relapse or Reinfection with Hepatitis C after Sustained Virologic Response: Meta-analysis of 49 Studies in 8534 Patients) They found:

•HCV mono-infected persons with low risk of exposure to the virus had a 1.14% reinfection rate 

•HCV mono-infected persons who injected drugs or prisoners had a 13.22% reinfection rate 

•HIV/HCV co-infected persons had a 21.72% reinfection rate

•All of the patients reviewed were treated with the dual regimen of pegylated interferon and ribavirin. 

The best way to avoid reinfection is to reduce risky behaviors that may expose you to hepatitis C. Never share needles or syringes. Do not share injection or inhaled drugs or equipment associated with it. Avoid blood-to-blood contact with others. Use condoms if you are sexually active with a new partner or with a partner who has used injection drugs.
If hepatitis C can live on a surface for up to 63 days, then shouldn’t I change my toothbrush (razor, cuticle scissors) during treatment, particularly when I am nondetectable. I don’t want to reinfect myself.

I haven’t seen a single study on this. There is probably no chance of reinfecting yourself with your own virus, particularly while you are taking antiviral medication. Also, the chances of hepatitis C being viable on a toothbrush, razor, or other personal instrument are extremely slim. Add to this the low reinfection rate, and I’d say the chances of self-reinfection are slim to none. 

However, I had hepatitis C once, and I know full well that sometimes we just don’t care what science says. It won’t hurt you to be overly cautious, and if you want to change these items, then go ahead. Rather than throw away perfectly good personal care items, you can store them for a few months and then use them later. You can also clean them with one part bleach to ten parts water.   

I just finished HCV treatment, but my viral load was detectable at week 8 and 12.  Does this mean my chances of being cured are low?

No. In the old days, back when treatment was long and used interferon, there were clear milestones that helped us know what our chances were of permanently clearing hepatitis C. Now with new direct-acting antivirals (DAAs), things have changed. Research by the NIH Clinical Center showed that low levels of HCV RNA at the end of treatment are not predictive of treatment response among patients with hepatitis C virus treated with interferon-free regimens. (Clinical Infectious Diseases, March 2, 2015).  Harvoni was used in this study, but the trend is likely to apply to all treatments using HCV DAAs. 

For years I thought I had genotype 1a, but a recent genotype test revealed I have 1b. How did this happen? 

It may be that you have more than one genotype at the same time. When this occurs, often the genotype test shows whichever genotype is more predominate, and sometimes the genotype can switch. 

Having more than one HCV genotype is not rare, with studies placing it in the 5 to 10% range. There are various ways a person could have more than one hepatitis C genotype: 

•Dual infection –This occurs when a person is infected with more than one hep C genotype at the same time. Hemophiliacs who received clotting factors, which are derived from thousands of sources, were at risk for dual infections. 

•Co-infection – This happens when someone is exposed from two different sources of hep C within a short time span, and acquires hep C from a second source before the first infection is established.

•Superinfection – Someone whose hepatitis C infection is established, and then they are infected with another genotype. 

There is also something called HCV recombination. In this situation, a person may be co-infected with more than one HCV genotype, and the viruses exchange genetic material. 
If I have more than one genotype, how do I know which treatment is best for me? 

If only one genotype shows up on the test, your doctor will treat you based on that genotype. If more than one genotype is apparent, then likely your doctor will recommend a regimen based on the harder to treat genotype. 
  
Will the Giants win the series this year? 

I admit, no one has ever asked me this, but they should. Lying awake worrying about hep C makes no sense, especially when there are more important issues to lose sleep over, such as whether the Giants will win the series again. 

QUOTE:
Sustained Viral Response (SVR) equals a cure, and that once gone, hepatitis C does not return unless there is exposure to a new infection. 

Lucinda K. Porter, RN, is a long-time contributor to the HCV Advocate and author of 
Free from Hepatitis C and Hepatitis C One Step at a Time. Her blog is www.LucindaPorterRN.com

Ongoing Real World Study Reports High Sustained Viral Response Rates with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) in Genotype 1 Hepatitis C Patients

Interim results from the independent AMBER study demonstrated 98 percent (n=39/40) SVR(12) rate in patients who completed a 12- or 24-week treatment regimen and 12 weeks follow-up
Real world interim data presented at the Viral Hepatitis Congress supports findings from previous HCV genotype 1 Phase 3 clinical trials with VIEKIRAX + EXVIERA
NORTH CHICAGO, Illinois, Sept. 11, 2015 /PRNewswire/ -- New real world interim data from the independent AMBER study were presented for AbbVie's VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets) with or without ribavirin (RBV) in genotype 1 (GT1) chronic hepatitis C virus (HCV) infected patients. The primary endpoint of the study is the percentage of patients achieving sustained virologic response at 12 weeks post-treatment (SVR12). This study of Polish patients who reached post-treatment at week 12 (n=40 of 186 enrolled to date), demonstrated 98 percent (n=39/40) SVR12.1 These results further help to support the GT1 data shown in AbbVie's Phase 3 clinical trial development program. Interim data from the AMBER study were presented at the Viral Hepatitis Congress in Frankfurt, Germany.

Read more.....

Sunday, September 13, 2015

8 simple ways for Hispanics to stay healthy

Many of these examples could be applied to people living with hepatitis C (AF)


In May, the first national study on Hispanics and their health was released by the U.S. Centers for Disease Control and Prevention (CDC).The surprising results showed that Hispanics are generally healthier and have a longer life expectancy than non-Hispanic whites, though we do have some areas to grow in.

"Although Hispanics have lower overall drinking rates compared with white non-Hispanics, when they do drink, on average they have higher rates of binge drinking," says Dr. Ken Dominguez, a medical epidemiologist with the CDC and lead author of the report. More surprising news? The study revealed that Hispanics are affected specifically by certain conditions, with high rates of obesity and diabetes contributing to the two leading causes of death: cancer and heart disease.

That may sound alarming, but the study provides ways to target the health risks — some of them symptomless, some of them woven into the festive fabric of our culture — that we face. After all, knowledge is power. "Being Hispanic does not have to determine your quality of life," says Dominguez, who advises us to "take charge of your own health, practice healthy behaviors."

Read more.....

Friday, September 11, 2015

Warning to Scots against hep C as health chiefs vow to eradicate 'silent killer'

RESIDENTS in the west of Scotland at risk of hepatitis C are being urged to get tested against the “silent killer”.

The number of new cases of the infection diagnosed in the Greater Glasgow area have risen in a year by about 5% - from 623 in 2013 to 656 last year.

It is estimated that overall 37,000 people have hep C in Scotland – 20,000 diagnosed and 17,000 undiagnosed.

About 40% of Scottish cases are in the Greater Glasgow area.

Read more...

Can Indian generic makers find gold with a blockbuster Hepatitis C drug?

For patients with Hepatitis C, Dr Parveen Malhotra prescribes a tablet that doctors say is revolutionising the treatment paradigm for the dreaded liver ailment. The hepatologist from Haryana's Rohtak town too has reported a higher cure rate since switching to the orally administered sofosbuvir from the injectable interferon five months ago.

According to World Health Organization data, hepatitis C kills half a million people a year and infects 150 million globally. Screening often includes costly multiple tests without which the ailment often goes undetected. In this backdrop, say doctors, sofosbuvir, is proving to be a magic bullet, unlike some of the alternatives that came with a host of side effects.

"This molecule (sofosbuvir) is revolutionary. Earlier we used to treat with interferon therapy, but here you have for the first time a therapy in oral form. With this molecule the ease of treatment has improved," said Dr Mandar Kubal, director of Mumbai based Infectious Diseases & Pulmonary Care.



Read more...

Thursday, September 10, 2015

Canada: Psychosis, Hepatitis C linked to high death rate in Downtown Eastside: UBC

The mortality rate in the Downtown Eastside is eight times the national average, according to a new UBC study that followed 371 people for about four years. 
 
The death rate in the Downtown Eastside is eight times higher than the Canadian average, and treatable problems are linked to mortality, according to research from the University of British Columbia published last month.

Psychosis and liver problems related to hepatitis C were the highest risk factors for mortality, according to the study of 371 people over about four years.

Researchers recruited the participants from single-room occupancy hotels and the Downtown Community Court. Thirty-one of them died.